degarelix acetate (firmagon) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
DEGARELIX (FIRMAGON®) is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids. It is a GnRH receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. DEGARELIX (FIRMAGON®) is effective in achieving and maintaining testosterone suppression below the castration level of 50 ng/dL and is indicated for the treatment of patients with advanced prostate cancer.   NCATS

Chemistry

  • SMILES: CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O
  • InChIKey: MEUCPCLKGZSHTA-XYAYPHGZSA-N
  • Mol. Mass: 1632.29
  • ALogP: Missing data
  • ChEMBL Molecules:
    degarelix  
    degarelix acetate  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

ac-2nal-4cpa-3pal-ser-4aph(hydroorotyl)-4aph(carbamoyl)-leu-ilys-pro-ala-nh2 | acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide | asp3550 | degarelix | degarelix acetate | fe200486 | fe 200486 | fe-200486 | fe-200486 (free base) | firmagon | gonax | uglypeptide1

Organizations (78)

Research & Development (78)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Prostatic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Androgen Antagonists (Phase 2)

Androgens (Phase 1)

Breast Neoplasms (Phase 2)

Breast Neoplasms, Male (Phase 2)

Carcinoma, Transitional Cell (Phase 1)

Cardiovascular Diseases (Phase 4)

Castration (Phase 3)

COVID-19 (Phase 2)

Endometriosis (Phase 3)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 2)

Infertility (Phase 3)

Infertility, Female (Phase 2)

Neoadjuvant Therapy (Phase 2)

Neoplasm Metastasis (Phase 3)

Ovarian Hyperstimulation Syndrome (Phase 3)

Polycystic Ovary Syndrome (Phase 3)

Pregnancy, Ovarian (Phase 3)

Prostatectomy (Phase 2)

Prostatic Hyperplasia (Phase 2)

Prostatic Neoplasms ()

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Urinary Tract Infections (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 106
  • # of Trial Organizations: 78

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue